219 related articles for article (PubMed ID: 23472826)
1. Effects of the antianginal drug, ranolazine, on the brain sodium channel Na(V)1.2 and its modulation by extracellular protons.
Peters CH; Sokolov S; Rajamani S; Ruben PC
Br J Pharmacol; 2013 Jun; 169(3):704-16. PubMed ID: 23472826
[TBL] [Abstract][Full Text] [Related]
2. Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations.
Kahlig KM; Lepist I; Leung K; Rajamani S; George AL
Br J Pharmacol; 2010 Nov; 161(6):1414-26. PubMed ID: 20735403
[TBL] [Abstract][Full Text] [Related]
3. State- and use-dependent block of muscle Nav1.4 and neuronal Nav1.7 voltage-gated Na+ channel isoforms by ranolazine.
Wang GK; Calderon J; Wang SY
Mol Pharmacol; 2008 Mar; 73(3):940-8. PubMed ID: 18079277
[TBL] [Abstract][Full Text] [Related]
4. Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels.
Kahlig KM; Hirakawa R; Liu L; George AL; Belardinelli L; Rajamani S
Mol Pharmacol; 2014 Jan; 85(1):162-74. PubMed ID: 24202911
[TBL] [Abstract][Full Text] [Related]
5. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability.
Estacion M; Waxman SG; Dib-Hajj SD
Mol Pain; 2010 Jun; 6():35. PubMed ID: 20529343
[TBL] [Abstract][Full Text] [Related]
6. Proton-dependent inhibition of the cardiac sodium channel Nav1.5 by ranolazine.
Sokolov S; Peters CH; Rajamani S; Ruben PC
Front Pharmacol; 2013; 4():78. PubMed ID: 23801963
[TBL] [Abstract][Full Text] [Related]
7. Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine.
Rajamani S; Shryock JC; Belardinelli L
Channels (Austin); 2008; 2(6):449-60. PubMed ID: 19077543
[TBL] [Abstract][Full Text] [Related]
8. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action.
Fredj S; Sampson KJ; Liu H; Kass RS
Br J Pharmacol; 2006 May; 148(1):16-24. PubMed ID: 16520744
[TBL] [Abstract][Full Text] [Related]
10. Ranolazine and late cardiac sodium current--a therapeutic target for angina, arrhythmia and more?
Makielski JC; Valdivia CR
Br J Pharmacol; 2006 May; 148(1):4-6. PubMed ID: 16520741
[TBL] [Abstract][Full Text] [Related]
11. Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action.
Beyder A; Strege PR; Reyes S; Bernard CE; Terzic A; Makielski J; Ackerman MJ; Farrugia G
Circulation; 2012 Jun; 125(22):2698-706. PubMed ID: 22565935
[TBL] [Abstract][Full Text] [Related]
12. Effects of ranolazine on cloned cardiac kv4.3 potassium channels.
Kim HJ; Ahn HS; Choi JS; Choi BH; Hahn SJ
J Pharmacol Exp Ther; 2011 Dec; 339(3):952-8. PubMed ID: 21940646
[TBL] [Abstract][Full Text] [Related]
13. Class I/B antiarrhythmic property of ranolazine, a novel antianginal agent, in dog and human cardiac preparations.
Szél T; Koncz I; Jost N; Baczkó I; Husti Z; Virág L; Bussek A; Wettwer E; Ravens U; Papp JG; Varró A
Eur J Pharmacol; 2011 Jul; 662(1-3):31-9. PubMed ID: 21550338
[TBL] [Abstract][Full Text] [Related]
14. Ranolazine: an antianginal drug with antiarrhythmic properties.
Tamargo J; Caballero R; Delpón E
Expert Rev Cardiovasc Ther; 2011 Jul; 9(7):815-27. PubMed ID: 21809962
[TBL] [Abstract][Full Text] [Related]
15. Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants.
El-Bizri N; Kahlig KM; Shyrock JC; George AL; Belardinelli L; Rajamani S
Channels (Austin); 2011; 5(2):161-72. PubMed ID: 21317558
[TBL] [Abstract][Full Text] [Related]
16. Antiepileptic activity of preferential inhibitors of persistent sodium current.
Anderson LL; Thompson CH; Hawkins NA; Nath RD; Petersohn AA; Rajamani S; Bush WS; Frankel WN; Vanoye CG; Kearney JA; George AL
Epilepsia; 2014 Aug; 55(8):1274-83. PubMed ID: 24862204
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.
Maier LS
J Cardiovasc Pharmacol; 2009 Oct; 54(4):279-86. PubMed ID: 19333133
[TBL] [Abstract][Full Text] [Related]
18. Should ranolazine be used for all patients with ischemic heart disease or only for symptomatic patients with stable angina or for those with refractory angina pectoris? A critical appraisal.
Thadani U
Expert Opin Pharmacother; 2012 Dec; 13(17):2555-63. PubMed ID: 23121448
[TBL] [Abstract][Full Text] [Related]
19. Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine.
Hirakawa R; El-Bizri N; Shryock JC; Belardinelli L; Rajamani S
Neuropharmacology; 2012 Jun; 62(7):2251-60. PubMed ID: 22313527
[TBL] [Abstract][Full Text] [Related]
20. Effects of ranolazine, a novel anti-anginal drug, on ion currents and membrane potential in pituitary tumor GH(3) cells and NG108-15 neuronal cells.
Chen BS; Lo YC; Peng H; Hsu TI; Wu SN
J Pharmacol Sci; 2009 Jul; 110(3):295-305. PubMed ID: 19609066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
